Abstract

Proton pump inhibitors are a widely used in clinical practice, and are taken by millions of patients around the world for a long time. While proton pump inhibitors are well-tolerated class of drugs, the number of publications has been raised about adverse renal effects, specially their association with acute tubulointerstitial nephritis. It is one of the leading causes of acute renal injury and have catastrophic long-term consequences called chronic kidney disease. In this review, we consider epidemiology, pathogenesis, diagnostic criteria (including biopsy and morphological pattern), clinical manifestations and treatment of proton pump inhibitors-induced acute tubulointerstitial nephritis. A subclinical course without classical manifestations of a cell-mediated hypersensitivity reaction (fever, skin rash, eosinophilia, arthralgia) is characteristic of acute tubulointerstitial nephritis. Increased serum creatinine, decreased glomerular filtration rate, electrolyte disorders, pathological changes in urine tests are not highly specific indicators, but allow to suspect the development of acute tubulointerstitial nephritis. The “gold” standard of diagnosis is the intravital morphological examination of the kidney tissue. Timely diagnosis and immediate discontinuation of the potentially causative drug is the mainstay of therapy and the first necessary step in the early management of suspected or biopsy-proven drug-induced acute tubulointerstitial nephritis. The usage of proton pump inhibitors should be performed only on strict indications with optimal duration of treatment and careful monitoring of kidney function. Multiple comorbidities (older age, heart failure, diabetes, cirrhosis, chronic kidney disease, hypovolemia) increase potential nephrotoxicity. Awareness of this iatrogenic complication will improve diagnosis of proton pump inhibitors-induced acute tubulointerstitial nephritis by multidisciplinary specialists and increase the possibility of successful treatment.

Highlights

  • Ингибиторы протонной помпы широко используются в клинической практике и принимаются миллионами пациентов во всем мире в течение длительного периода времени

  • While proton pump inhibitors are well-tolerated class of drugs, the number of publications has been raised about adverse renal effects, specially their association with acute tubulointerstitial nephritis

  • Diagnosis and immediate discontinuation of the potentially causative drug is the mainstay of therapy and the first necessary step in the early management of suspected or biopsy-proven drug-induced acute tubulointerstitial nephritis

Read more

Summary

RENAL SAFETY OF PROTON PUMP INHIBITORS

Ингибиторы протонной помпы широко используются в клинической практике и принимаются миллионами пациентов во всем мире в течение длительного периода времени. В данном обзоре рассмотрены эпидемиология, патогенетические варианты развития, критерии диагностики (в том числе оценка морфологической картины), клинические проявления и лечение острого тубулоинтерстициального нефрита, индуцированного приемом ингибиторов протонной помпы. Своевременная диагностика и незамедлительная отмена ингибиторов протонной помпы является первоочередными лечебными подходами при персистенции клинических проявлений острого тубулоинтерстициального нефрита. Привлечение внимания многопрофильных специалистов к проблеме развития острого тубулоинтерстициального нефрита, индуцированного приемом ингибиторов протонной помпы, улучшит раннюю диагностику и лечение данного заболевания. Multiple comorbidities (older age, heart failure, diabetes, cirrhosis, chronic kidney disease, hypovolemia) increase potential nephrotoxicity Awareness of this iatrogenic complication will improve diagnosis of proton pump inhibitors-induced acute tubulointerstitial nephritis by multidisciplinary specialists and increase the possibility of successful treatment

REVIEW ARTICLES
Эпидемиология лекарственного ОТИН
Патогенез лекарственного ОТИН
Морфологическая картина лекарственного ОТИН
Клиническая картина лекарственного ОТИН
Диагностика лекарственного ОТИН
Течение и прогноз лекарственного ОТИН
ИПП и хроническая болезнь почек
СИМПТОМАТИЧЕСКАЯ ТЕРАПИЯ
Findings
ИММУНОСУПРЕССИВНАЯ ТЕРАПИЯ

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.